PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030341 / 12362959 Report Date : 24/Mar/2025 05:24PM
Referred By : Dr. Report Status : Final Report
Sample Type : Whole Blood-EDTA

HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method

Complete Blood Count

Hemoglobin 13.8 g/dL 13.0-17.0 Cyanide Free SLS
RBC 4.87 10^6/cu.mm 4.5 - 5.5 Impedance
HCT 42.4 % 40 - 50 Calculated
MCV 87.2 fL 83 - 101 RBC pulse measurement
MCH 28.4 pg 27 - 32 Calculated
MCHC 32.5 g/dL 31.5 - 34.5 Calculated
RDW-CV 14.4 % 11.6-14 Calculated
Total Leucocyte Count 7.47 10^3/µL 4 - 10 Impedance
Differential Leucocyte Count
Neutrophils 51.5 % 40-80 DHSS/Microscopy
Lymphocytes 38.4 % 20-40 DHSS/Microscopy
Monocytes 7.7 % 2-10 DHSS/Microscopy
Eosinophils 2.2 % 1-6 DHSS/Microscopy
Basophils 0.2 % 0-2 Impedance/Microscopy
Absolute Leucocyte Count
Absolute Neutrophil Count 3.85 10^3/µL 2-7 Calculated
Absolute Lymphocyte Count 2.87 10^3/µL 1-3 Calculated
Absolute Monocyte Count 0.58 10^3/µL 0.2 - 1 Calculated
Absolute Eosinophil Count 0.16 10^3/µL 0.02 - 0.5 Calculated
Absolute Basophil Count 0.01 10^3/µL 0.02-0.1 Calculated
Platelet Count 369 10^3/µL 150-410 Impedance /Microscopy
MPV 10.6 fL 6.5 - 12 Calculated
PDW 18.4 fL 9-17 Calculated

Comment:
As per the recommendation of International council for Standardization in Hematology, the differential leucocyte counts are
additionally being reported as absolute numbers of each cell in per unit volume of blood.
DHSS : Double Hydrodynamic Sequential System

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 1 of 8
 PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030341 / 12362959 Report Date : 24/Mar/2025 05:21PM
Referred By : Dr. Report Status : Final Report
Sample Type : WHOLE BLOOD-EDTA

HAEMATOLOGY
Test Name Result Unit Bio. Ref. Interval Method

HbA1c (Glycosylated Hemoglobin)

Glycosylated Hemoglobin (HbA1c) 5.6 % 4 - 5.6 HPLC (NGSP certified)
Estimated average glucose (eAG) 114.02 mg/dL Calculated

Comment:
Interpretation: HbA1c%

≤5.6 Normal
5.7-6.4 At Risk For Diabetes
≥6.5 Diabetes

Adapted from American Diabetes Association.

Comments:
A 3 to 6 monthly monitoring is recommended in diabetics. People with diabetes should get the test done more often if their blood
sugar stays too high or if their healthcare provider makes any change in the treatment plan. HbA1c concentration represent the
integrated values for blood glucose over the preceding 8-12 weeks and is not affected by daily glucose fluctuation, exercise &
recent food intake.
Please note, Glycemic goal should be individualized based on duration of diabetes, age/life expectancy, comorbid conditions,
known CVD or advanced microvascular complications, hypoglycemia unawareness, and individual patient considerations.

Factors that interfere with HbA1c Measurement: Hemoglobin variants, elevated fetal hemoglobin (HbF) and chemically modified
derivatives of hemoglobin (e.g. carbamylated Hb in patients with renal failure) can affect the accuracy of HbA1c measurements.

Factors that affect interpretation of HbA1c Measurement: Any condition that shortens erythrocyte survival or decrease mean
erythrocyte age (e. g., recovery from acute blood loss, hemolytic anemia, HbSS, HbCC, and HbSC) will falsely lower HbA1c test
results regardless of the assay method used. Iron deficiency anemia is associated with higher HbA1c.

Note: Presence of Hemoglobin variants and/or conditions that affect red cell turnover must be considered, particularly when the
HbA1c result does not correlate with the patient's blood glucose levels.

• HPLC - High performance liquid chromatography

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 2 of 8
PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030342 / 12362959 Report Date : 24/Mar/2025 05:53PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Lipid Profile
Cholesterol - Total 167 mg/dL Low (desirable): < 200 Enzymatic
Moderate (borderline)
200–239
High: >/= 240
Triglycerides 107 mg/dL Normal: <150, GPO
Borderline: 150 - 199,
High:200-499,
Very High>=500
Cholesterol - HDL 33 mg/dL Undesirable/high risk <40 Cholesterol Esterase
Desirable/low risk>=60
Cholesterol - LDL 113 mg/dL Desirable: <100 Calculated
Above desirable: 100 -
129
Borderline high : 130 -
159
High : 160 - 189
Very high : >=190
Cholesterol- VLDL 21 mg/dl <30 Calculated
Cholesterol : HDL Cholesterol 5.1 Ratio Desirable : 3.5-4.5 Calculated
High Risk : >5
LDL : HDL Cholesterol 3.45 Ratio Desirable : 2.5-3.0 Calculated
High risk : >3.5
Non HDL Cholesterol 134 mg/dl Desirable:< 130, Calculated
Above Desirable:130 -
159,
Borderline High:160 -
189,
High:190 - 219,
Very High: >= 220

Comment:
•Lipid profile measurements in the same patient can show physiological & analytical variations. It is recommended that 3 serial

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 3 of 8
PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030342 / 12362959 Report Date : 24/Mar/2025 05:53PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
samples 1 week apart may be tested.
•Indians are at a high risk of developing atherosclerotic cardiovascular disease (ASCVD); at a much earlier age and more severe
with high mortality. Dyslipidemia (abnormal lipid profile) is the major risk factor and found in almost 80% Indians.
•Total cholesterol is the total amount of cholesterol in blood comprising of HDL, LDL-C, and VLDL.
•LDL Cholesterol (LDL-C) or “bad”cholesterol contributes most significantly to atherosclerosis leading to heart disease or
stroke and is the primary target for reducing risk for cardiovascular disease.
•High-density lipoprotein (HDL) or “good” cholesterol can lower risk of heart disease and stroke.
•Triglyceride (TG) level also plays a major role in CVD. Indians are more prone to Atherogenic dyslipidemia, a condition
associated with high TG, low HDL-C and high LDL-C; this is associated with diabetes, metabolic syndrome and insulin resistance.
Hence high triglyceride levels also need to be treated.
•Non-HDL-Cholesterol (Non-HDLC) measures all plaque forming lipoproteins (e.g. remnants, LDL-C, VLDL, Lp(a), Apo-B).
Monitoring of Non-HDLC is important in patients with high TG (e.g. diabetics, obese persons) and those already on statin
therapy.
•Lipid Association of India (LAI-2020) recommends:-

Screening of all Indians above the age of 20 years for CVD risk factors, esp. lipid profile.
Identification of Risk factors: Age (male ≥45 years, female ≥55 years); Family h/o heart disease at younger age (<55 yrs
in males, <65 yrs in female), Smoking/tobacco use, High blood pressure, Low HDL (males <40 mg/dl and females
<50mg/dl).
Fasting lipid profile is not mandatory for screening. Both fasting and non-fasting lipid profiles are equally important for
managing Indian patients.
Non-HDLC should be calculated in every subject. LAI recommends LDL-C as the primary target and Non-HDLC as the co-
primary target for initiating drug therapy.
Lifestyle modifications are of first and foremost importance for management and prevention of dyslipidemia. Among low
risk groups, treatment is started only after 3 months of lifestyle changes.
Testing for Apolipoprotein B, hsCRP, Lp(a ) should be considered for patients in moderate risk group.
Newer treatment goals based on Risk Groups and values of LDL-C and Non-HDLC

New treatment goals by Lipid Association of India (2020)

CONSIDER THERAPY (cut-off level) TREATMENT GOALS
Risk groups LDL-C (mg/dL) Non-HDLC (mg/dL) LDL-C (mg/dL) Non-HDLC (mg/dL)
<50 <80
Extreme Risk Gp Cat. A ≥50 ≥80
(Optional ≤30) (Optional ≤60)
Extreme Risk Gp Cat. B >30 >60 ≤30 ≤60
Very High Risk ≥50 ≥80 <50 <80
High Risk ≥70 ≥100 <70 <100
Moderate Risk ≥100 ≥130 <100 <130
Low risk ≥130* ≥160* <100 <130
*After an adequate non-pharmacological intervention for at least 3 months

•As per NCEP Expert Panel (2011) guidelines, universal screening for dyslipidemia is recommended for children between 9
- 11 yrs (repeat at 17-21 yrs). Screening is not recommended before the age of 2yrs. Above the age of 2 yrs, selective screening
is done in children with family history of premature CVD or risk factors like obesity, diabetes, and hypertension.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 4 of 8
PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030342 / 12362959 Report Date : 24/Mar/2025 05:53PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
Note: Reference Interval as per National Cholesterol Education Program (NCEP) Report.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 5 of 8
 PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030339 / 12362959 Report Date : 24/Mar/2025 05:06PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

LIVER FUNCTION TEST

Liver Function Test
Bilirubin-Total 0.30 mg/dL 0.2-1.2 Diazonium Salt
Bilirubin-Direct 0.13 mg/dL 0.11-0.42 Diazo
Bilirubin-Indirect 0.17 mg/dL 0.2-0.8 Calculated
Protein, Total 7.60 g/dL 6.0-8.0 Biuret
Albumin 4.60 g/dL 3.8-5.4 Bromocresol Green
Globulin 3.0 g/dl 2.1 - 3.9 Calculated
A/G Ratio 1.53 Ratio 0.8 - 2.1 Calculated
Aspartate Transaminase (SGOT) 26 U/L 14-35 NADH w/o P-5’-P
SGPT (Alanine Transaminase) 49 U/L 8-22 NADH w/o P-5’-P
SGOT/SGPT 0.53 Ratio Calculated
Alkaline Phosphatase 64 U/L 56-167 Para-Nitrophenyl
Phosphate
Gamma Glutamyltransferase (GGT) 33 U/L 10-33 L-gamma-glutamyl-3-
Carboxy-4-Nitroanilide

Comment:

Raised ALT and AST indicate hepatocellular damage (e.g. viral or drugs etc). ALT is more liver-specific while AST is also
found in heart, skeletal muscle, and kidney. Mild elevation (less than twice normal) often resolves on its own. Fatty liver
disease (especially with metabolic syndrome) is a common cause in asymptomatic cases. Certain drugs (paracetamol,
statins), herbal supplements, energy drinks, and antibiotics may also affect liver function.
SGOT/SGPT Ratio: Typically <1 in healthy individuals (vary between 0.7-1.4; higher in women than men). High SGPT (ratio
<1) seen in acute or chronic hepatitis, autoimmune disorders, medications, toxins while ratio >1 indicates alcoholic
hepatitis, cirrhosis, metastasis or non-hepatic issues (hemolytic diseases, CVS disorders).
Elevated Alkaline Phosphatase and GGT: Suggest cholestatic diseases (e.g. bile duct obstruction, primary biliary
cirrhosis etc.) and can also be due to bone disease, pregnancy, chronic renal failure, malignancy, and congestive heart
failure.
High Bilirubin: Indicates jaundice due to increased RBC breakdown, liver damage (e.g., infections, toxins), or cholestasis
(e.g., gallstones, tumors).

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 6 of 8
PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030339 / 12362959 Report Date : 24/Mar/2025 05:06PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method
High Protein Levels: Seen in dehydration (e.g., severe vomiting, diarrhea) or increased production (e.g., inflammation,
hematopoietic neoplasms). Low protein and albumin: Result from impaired synthesis (liver disease), decreased intake,
tissue damage, malabsorption, or increased renal excretion.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 7 of 8
 PO No :PO2935496411-942

Name : Mr.HARSHUL DHINGRA Client Name : 1 MG INTEGRATION - GURUGRAM

Age/Gender : 18/Male Registration Date : 24/Mar/2025 12:18PM
Patient ID : 1MG629998 Collection Date : 24/Mar/2025 11:59AM
Barcode ID/Order ID : D18030339 / 12362959 Report Date : 24/Mar/2025 06:20PM
Referred By : Dr. Report Status : Final Report
Sample Type : Serum

BIOCHEMISTRY
Test Name Result Unit Bio. Ref. Interval Method

Creatinine
Creatinine 0.71 mg/dL 0.69-1.10 Kinetic Alkaline Picrate

Comment:

Creatinine is a more specific and sensitive indicator of renal disease than Blood Urea Nitrogen.

Uses:

To diagnose renal insufficiency;

Adjusting dosage of renally excreted medications.
Monitoring renal transplant recipients.
Serum creatinine levels are a proxy for reduced skeletal muscle mass.
Serum creatinine measurement is used in estimating the Glomerular Filtration Rate (GFR) for people with Chronic Kidney
disease (CKD) and those with risk factors for CKD (Diabetes Mellitus, hypertension, cardiovascular disease, and family
history of kidney disease).

Increased In: Blockage in the urinary tract, Pre- and postrenal azotemia, Impaired kidney function, Loss of body fluid
(dehydration), Muscle diseases such as gigantism, acromegaly.
Decreased In: Pregnancy, certain drugs (e.g., cimetidine, trimethoprim), Myasthenia Gravis, Muscular dystrophy.

*** End Of Report ***

Conditions of Laboratory Testing & Reporting:
Test results released pertain to the sample, as received. Laboratory investigations are only a tool to facilitate in arriving at a diagnosis and should
be clinically correlated by the interpreting clinician. Result delays may happen because of unforeseen or uncontrollable circumstances. Test report
may vary depending on the assay method used. Test results may show inter-laboratory variations. Test results are not valid for medico-legal
purposes. Please mail your queries related to test results to Customer Care mall ID care@1mg.com

Disclaimer: Results relate only to the sample received. Test results marked "BOLD" indicate abnormal results i.e. higher or lower than normal. All
lab test results are subject to clinical interpretation by a qualified medical professional. This report cannot be used for any medico-legal purposes.
Partial reproduction of the test results is not permitted. Also, TATA 1mg Labs is not responsible for any misinterpretation or misuse of the
information. The test reports alone may not be conclusive of the disease/condition, hence clinical correlation is necessary. Reports should be
vetted by a qualified doctor only.

This test has been performed at

TATA 1MG OKHLA
Address: 2nd Floor, B-225, Okhla Phase I,
Okhla Industrial Estate, New Delhi, Delhi
110020

Page 8 of 8
 Ensuring accuracy IN every single report
Following a 3-step review process:

Advanced systems & Experienced lab experts Each report undergoes

cutting-edge technology analyze and technicians conduct rigorous medical scrutiny & is
results with precision comprehensive reviews signed off by a doctor

Have concerns regarding the report?

Reach out to our care team at care@1mg.com
or chat with us
CONNECT NOW >

Accurate Testing, Assured Quality: Diagnostics Precision

Stringent quality control Cutting-edge technology Experienced lab staff

Measures meeting Robust healthcare systems 30+ medical professionals
international norms of safety equipped with calibrated & with a collective
guidelines well-maintained machinery experience of 200+ years

Verified test procedures External assessments Trained phlebotomists

Highly standardized test Thorough third-party Ensuring smooth sample
procedures following CLSI* assessment by authorized collection experience &
guidelines experts pre-analytical precision

Claim FREE doctor consultation

Watch how
Consult top doctors from
the comfort of your home
we take care of
your sample
SCHEDULE NOW>

Get Second Opinion Order Medicines EXPLORE NOW >

Explore Financial Need Help?

Book Lab Tests
Support & more 1800-102-1618

*Clinical & Laboratory Standards Institute T&C Apply

 Running Low on Vitamin D?
Choose clinically proven , ready-to-drink1
Vitamin D3 with 34% better absorption2

34% Better Absorption*2

Palatable Taste1

Sugar Free1

LIMITED OFFER

MAT-IN-2500204 v1.0 02/25

*With DePURA, 34% higher Vitamin D3 levels are achieved as compared to
conventional formulation.
Reference: 1. Data on File 2. Marwaha, Raman K., et al. "Efficacy of micellized
vs. fat-soluble vitamin D3 supplementation in healthy school children from
20 % OFF
ON TATA 1MG
SHOP NOW!
use code:
DEP20
Northern India."Journal of Pediatric Endocrinology and Metabolism 29.12.

Are you getting

enough OMEGA 3

^ Stark KD, et al, progress in Lipid Research 2016

* Compared with competing products
to protect your heart?
Because 80%^ of people don’t!
# Optimal requirement of Omega-3 as mentioned by National Institutes
+ Reference from NCBI published article on comparative bioavailability

Choose Tata 1mg Salmon Omega 3 of Health. Dietary Supplement Label Database. 2015.

LDL

Reduces Improves Reduces

Triglyceride Levels Good Cholesterol Inflammation

Why Choose Us?

50% Higher Absorption+
with Triglyceride form 50% Lower
Saturated Fats*
Every batch
Tested and Certified

Upto 30% off Shop Now